Global Plasma Therapy Market-Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global plasma therapy market over the forecast period. This is due to the increasing number of product approvals in the region. For instance, on April 25, 2023, Biogen, a U.S.-based multinational biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients